OncoCyte (NASDAQ:OCX) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of OncoCyte (NASDAQ:OCX) in a research note issued to investors on Tuesday morning, Benzinga reports. Needham & Company LLC currently has a $4.25 target price on the stock.

Separately, StockNews.com began coverage on OncoCyte in a research report on Tuesday. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, OncoCyte currently has a consensus rating of “Hold” and an average target price of $4.06.

OncoCyte Stock Up 0.3 %

Shares of OncoCyte stock opened at $3.13 on Tuesday. The company has a 50 day moving average of $3.08 and a 200-day moving average of $2.94. OncoCyte has a 1-year low of $2.08 and a 1-year high of $4.34.

OncoCyte (NASDAQ:OCX) last issued its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%. The business had revenue of $0.10 million during the quarter.

Insider Buying and Selling

In other news, CFO Andrea S. James bought 33,670 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average cost of $2.97 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief financial officer now owns 33,670 shares of the company’s stock, valued at $99,999.90. The purchase was disclosed in a legal filing with the SEC, which is available at this link. In other OncoCyte news, CFO Andrea S. James purchased 33,670 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average cost of $2.97 per share, for a total transaction of $99,999.90. Following the transaction, the chief financial officer now owns 33,670 shares in the company, valued at $99,999.90. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were acquired at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the acquisition, the insider now owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 1.58% of the stock is currently owned by corporate insiders.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.